Anbogen Therapeutics

Private

TaipeiHealthcare & Life Scienceshttps://www.anbogen.com

Last Round

Series A

Extension

Jul 1, 2024

Total Funding Raised

$19.8M

Company Overview

Anbogen Therapeutics is a biotechnology company that develops precision cancer therapeutics to address unmet medical needs.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

precision oncologysmall-molecule inhibitorstyrosine kinase inhibitorTKIhistone deacetylase inhibitorHDAC inhibitornon-small cell lung cancerNSCLConcology drugsKRAS inhibitorsHER2 exon20 insertionclinical-stage biotechsolid tumorsdrug developmentcold tumorspeptide-drug conjugatePDCimmune checkpoint inhibitorscolorectal cancerbiotech licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Anbogen Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Anbogen Therapeutics Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Series A Extension	Jul 1, 2024
Series A	Jan 31, 2024

View all Funding Rounds

Anbogen Therapeutics Investors

Notable investors and investment history

Investor	Rounds
CDIB Capital International	Series A
National Development Fund	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Apr 13, 2026
Imofinostat shows potential to address chemo-resistance in Pancreatic Cancer.
Apr 13, 2026
Presented clinical trial data at the AACR conference.

View all signals

Anbogen Therapeutics Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Anbogen Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Anbogen Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersTaipei

Year Founded2019

Last FundingJul 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.